Sign in
WithdrawnPhase 4

Antimicrobial Revision in Persistent Febrile Neutropenia

Key facts

Who runs it
Wake Forest University Health Sciences
Trial code
Status
Withdrawn
Phase
Phase 4
Started
Aug 2024
Ended
Apr 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Meropenem
  • Micafungin
Record updated
19 September 2024
Why it stopped
Study was never initiated or activated - Reason was lack of funding

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • ≥ 18 years of age
  • Diagnosis of hematologic malignancy
  • Receiving chemotherapy as treatment of hematologic malignancy
  • Neutropenia defined as an absolute neutrophil count (ANC) ≤ 500 cells/mm3 or an ANC ≤ 1000 cells/mm3 with a predicted decline to < 500 cells/mm3 within 48 hours
  • Prescribed cefepime or piperacillin-tazobactam as initial treatment for febrile neutropenia
  • Persistent fever for ≥ 96 hours since initiation of cefepime or piperacillin-tazobactam OR recurrent fever that occurs ≥ 96 hours since initiation of cefepime or piperacillin-tazobactam (fever defined as single temperature of ≥ 38.3°C (101°F) or a temperature of ≥ 38°C (100.4°F) on two consecutive measures separated by at least one hour)
  • Receipt of posaconazole as neutropenia prophylaxis for at least 3 calendar days

Who cannot take part

  • Concomitant use of valproic acid
  • Previous enrollment in this study
  • Clinically or microbiologically confirmed infection at time of enrollment, For example, a positive culture or rapid diagnostic test, positive imaging (X-ray, CT, MRI) or biomarker, such as galactomannan, that is consistent with infection
  • History of infection with organism known to be resistant to meropenem or micafungin
  • Documented allergy to carbapenems or echinocandins
  • Uncontrolled seizure disorder
  • Pregnancy

About the trial

What the trial wants to find out

Febrile neutropenia is often seen in patients with hematologic malignancies who receive cytotoxic chemotherapy. These patients are usually placed on posaconazole prophylaxis upon starting chemotherapy. If an episode of febrile neutropenia occurs, generally an anti-pseudomonal beta lactam, like cefepime or piperacillin-tazobactam, is initiated. In patients who continue to fever on these agents, the optimal method of antimicrobial revision has yet to be determined.

The 2 groups in the trial

  • Meropenem ArmExisting treatment, for comparison

    Patients who meet inclusion criteria may be randomized to meropenem (routine standard of care) dose according to local dosing guidelines to include the use of extended-infusions and adjustments to account for renal function. Duration will be managed by the primary team.

    Treatment: Meropenem

  • Micafungin ArmExisting treatment, for comparison

    Patients who meet inclusion criteria may be randomized to micafungin dosed as 150mg intravenously every 24 hours according to local dosing guidelines. Duration will be managed by the primary team.

    Treatment: Micafungin

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Antimicrobial Revision in Patients With Persistent Febrile Neutropenia: A Prospective, Randomized Trial
Record updated
19 September 2024